Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03268954
Title Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

Azacitidine + MLN4924

Azacitidine

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.